We are live on ! Find out more

SpyGlass Pharma

SGP

Market cap $1.1B

32.88 USD

-0.44

1.32%

At close Updated Nov 13, 4:00 PM EST

1 day

-1.32%

5 days

-12.53%

1 month

37.46%

3 months

30.63%

6 months

38.04%

Year to date

24.55%

1 year

24.55%

5 years

24.55%

10 years

24.55%

About: SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.

Employees: 65

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

IRVINE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business highlights and financial results for the third quarter ended September 30, 2026.

SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

SpyGlass Pharma to Participate in Upcoming Investor Conferences

IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management team will participate in the following upcoming conferences: Stifel 2026 Healthcare Conference Date: Thursday, November 12, 2026Time: 8:00 a.m.

SpyGlass Pharma to Participate in Upcoming Investor Conferences

SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System

Groundbreaking 4-year safety and efficacy results: 37% reduction in mean intraocular pressure (IOP) across all dose groups 86% of patients remained off all topical IOP-lowering drops 90% of patients maintained ≥20/25 best corrected distance visual acuity (BCDVA) No product-related adverse events were reported IRVINE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines, today announced positive 4-year first-in-human (FIH) trial results for the Bimatoprost Drug Pad-IOL System (BIM-IOL System) in patients with mild-to-moderate open angle glaucoma (OAG) or ocular hypertension (OHT) undergoing routine cataract surgery.

SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System

SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability

IRVINE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”) announced today the acquisition of all the outstanding shares of common stock of Advanced Vision Science, Inc. (AVS), an ophthalmic medical device company and manufacturer of intraocular lenses (IOLs) and lens materials, for approximately $13 million in cash. This acquisition secures scalable commercial IOL manufacturing capacity for SpyGlass Pharma. AVS was a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd (Santen) and is the current supplier of SpyGlass Pharma's IOL in its two Phase 3 registrational trials evaluating the BIM-IOL System.

SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability

SpyGlass Pharma, Inc. (SGP) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

SpyGlass Pharma, Inc. (SGP) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

SpyGlass Pharma, Inc. (SGP) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

SpyGlass Pharma to Participate in Upcoming Investor Conferences

IRVINE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management team will participate in the following upcoming conferences: Wells Fargo 21 st Annual Healthcare Conference Date: Wednesday, September 9, 2026 Format: 1x1 Meetings only Citi's 2026 Biopharma Back to School Conference Date: Thursday, September 10, 2026Time: 10:40 a.m.

SpyGlass Pharma to Participate in Upcoming Investor Conferences

SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027. Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to start in the second half of 2026.

SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

SpyGlass Pharma Appoints Shannon Treviño as General Counsel

ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma or Company), a late-stage biopharmaceutical company, today announced the appointment of Shannon Treviño as general counsel. Ms. Treviño brings significant business-oriented legal experience and leadership that results in operating excellence for publicly traded companies at various stages of growth.

SpyGlass Pharma Appoints Shannon Treviño as General Counsel

SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing

ALISO VIEJO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced the appointment of Mike Pinder as vice president, marketing.

SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing

SpyGlass Pharma to Participate in Upcoming Investor Conferences

ALISO VIEJO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the executive management team will participate in the following upcoming conferences: Stifel 2026 Virtual Ophthalmology Forum Date: Tuesday, May 26, 2026Time: 2:00 p.m.

SpyGlass Pharma to Participate in Upcoming Investor Conferences

See News Rankings

Price charts implemented using Lightweight Charts™